← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2003First marketed drug
Apr 4, 2003First NDA
Apr 4, 2003Last known activity
May 30, 2025
Timeline
1940s
- Jan 1, 1947
LG— Founded
2000s
- Apr 4, 2003
gemifloxacin— NDA Organization
- Apr 4, 2003
gemifloxacin— NDA Secondary Org
Drugs by trial phase (67 distinct, 126 trials)
Phase 4 (14 own, 0 via acquisition)
Phase 3 (18 own, 0 via acquisition)
- allopurinol
- diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine
- etanercept
- glycine
- centella asiatica
- rosuvastatin
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- lc350189
- adalimumab
- linagliptin
- valsartan
- hyaluronic acid
- lercanidipine
- cisplatin
- haemophilus influenzae type b conjugate vaccine
- +3 more
Phase 2 (11 own, 0 via acquisition)
Phase 1 (22 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Coronary Syndrome
- Acute Kidney Injury
- Arthritis
- Arthritis, Rheumatoid
- Cerebral Palsy
- Colitis
- Colitis, Ulcerative
- Communicable Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diphtheria
- Dwarfism
- Dwarfism, Pituitary
- Dyslipidemias
- Endocrine System Diseases
- Essential Hypertension
- Gonadal Dysgenesis
- Gout
- Haemophilus Infections
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Hyperlipidemias
- Hyperlipoproteinemias
- Hypertension
- Hyperuricemia
- Infarction
- Infections
- Infertility
- Infertility, Female
- Influenza, Human
- Kidney Failure, Chronic
- Liver Diseases
- Malnutrition
- Myocardial Infarction
- Nausea
- Osteoarthritis
- Osteoarthritis, Knee
- Paralysis
- Pituitary Diseases
- Pneumococcal Infections
- Poliomyelitis
- Prader-Willi Syndrome
- Renal Insufficiency
- ST Elevation Myocardial Infarction
- Syndrome
- Tetanus
- Turner Syndrome
- Ulcer
- Urinary Bladder, Overactive
- Vomiting
- Whooping Cough
Marketed drugs (2)
Recent trials (50)
- NCT06947499Lead sponsorPhase 2/Phase 3May 30, 2025
- NCT06921395Lead sponsorPhase 4Feb 15, 2025
- NCT06743997Lead sponsorPhase 1Jan 15, 2025
- NCT06618196Lead sponsorPhase 2Oct 2, 2024
- NCT06332755Lead sponsorPhase 1Jun 5, 2024
- NCT06046443Lead sponsorPhase 2Dec 31, 2023
- NCT06041841Lead sponsorPhase 2Dec 31, 2023
- NCT06189404Lead sponsorPhase 1Oct 31, 2023
- NCT05952596Lead sponsorPhase 1Jul 17, 2023
- NCT05457946Lead sponsorPhase 2/Phase 3Feb 1, 2023
- NCT05431933Lead sponsorPhase 3Jan 31, 2023
- NCT05586971Lead sponsorPhase 3Jan 31, 2023
- NCT05586971Study directorPhase 3Jan 31, 2023
- NCT05586958Lead sponsorPhase 3Dec 31, 2022
- NCT05586958Study directorPhase 3Dec 31, 2022
Details
- Founded
- Seoul, KR Jan 1, 1947
- First NDA
- Apr 4, 2003
- Last known activity
- May 30, 2025